2024 World Conference on Lung Cancer (WCLC) - ePosters-EP.12A.42 Savolitinib Plus Osimertinib in EGFR-Mutant NSCLC with MET Overexpression and Acquired Resistance to Previous EGFR Inhibitor

EP.12A.42 Savolitinib Plus Osimertinib in EGFR-Mutant NSCLC with MET Overexpression and Acquired Resistance to Previous EGFR Inhibitor

Back to course

Pdf Summary

The study evaluates the efficacy and safety of Savolitinib, a selective MET TKI, combined with Osimertinib, in patients with EGFR-mutant, MET-overexpressed advanced non-small cell lung cancer (NSCLC) showing progression after previous EGFR-TKI treatment. MET amplification often contributes to resistance against EGFR inhibitors like Osimertinib. This retrospective study included six patients whose re-biopsy revealed acquired MET overexpression and who were subsequently treated with Savolitinib and Osimertinib.<br /><br />Results showed that all patients achieved partial responses, with treatment ongoing for three of them. The median progression-free survival (PFS) was 13.7 months, and the median follow-up duration was 20.5 months. Safety data indicated that common adverse events (AEs) included edema, nausea, and fatigue, mostly grades 1 or 2. One patient experienced hypersensitivity, leading to dose adjustment and ongoing treatment with prophylactic dexamethasone.<br /><br />The study highlighted Savolitinib's potential when combined with Osimertinib to manage MET-overexpressed, EGFR mutation-positive NSCLC following EGFR-TKI resistance. Tissue re-biopsy played a crucial role in identifying resistance mechanisms, thereby guiding subsequent therapies for these patients. This combination offers a promising therapeutic avenue, presenting an acceptable safety profile and significant clinical benefits for this patient cohort.

Asset Subtitle

Yong Mao

Meta Tag

Speaker Yong Mao

Topic Metastatic Non-small Cell Lung Cancer – Targeted Therapy

Keywords

Savolitinib

Osimertinib

EGFR-mutant

MET-overexpressed

non-small cell lung cancer

EGFR-TKI resistance

MET amplification

partial responses

progression-free survival

adverse events